Poller L, Thomson J M, Bodzenta A, Easton A C, Latallo Z S, Chmielewska J
Br J Haematol. 1981 Sep;49(1):69-75. doi: 10.1111/j.1365-2141.1981.tb07198.x.
A comparison has been made between the prothrombin time test using British Comparative Thromboplastin (BCT) and a chromogenic substrate assay for factor VII in the assessment of laboratory control of oral anticoagulants in short-term and long-term patients. Opportunity was also taken to compare the findings with parallel results obtained with the venous Thrombotest technique and a specific clotting assay for factor VII. There was good agreement between the amidolytic factor VII assay, using a method modified from Seligsohn et al (1978) with the Quick test using BCT and Thrombotest in 60 long-term patients. Tests in 53 patients within the first 3 weeks of starting oral anticoagulant administration gave less satisfactory agreement between the above amidolytic method and the conventional tests. In contrast, there was a good correlation between the two conventional tests in both groups and also between the clotting and amidolytic factor VII method. Although the results are an improvement on previous, less satisfactory correlations between the BCT prothrombin time method and amidolytic assays for factor II and X, the present study indicates the limitations of a specific clotting assay versus a broad spectrum extrinsic clotting test in oral anticoagulant control. While not warranting the routine use of the chromogenic assay for factor VII in place of the prothrombin time using BCT, the factor VII amidolytic assay offers a limited but dependable guide to dosage in long-term patients. The complexity of the technique in its present form militates against its adoption for routine anticoagulant control in hospital laboratories.
在短期和长期口服抗凝剂患者的实验室监测评估中,对使用英国比较凝血活酶(BCT)的凝血酶原时间试验与因子VII的发色底物测定法进行了比较。还借此机会将这些结果与通过静脉血栓试验技术和因子VII特异性凝血测定法获得的平行结果进行比较。在60例长期患者中,采用经Seligsohn等人(1978年)改良的方法进行的酰胺水解因子VII测定法,与使用BCT的Quick试验和血栓试验之间具有良好的一致性。在开始口服抗凝剂治疗的前三周内对53例患者进行的检测显示,上述酰胺水解法与传统检测法之间的一致性不太令人满意。相比之下,两组中两种传统检测法之间以及凝血和酰胺水解因子VII法之间均具有良好的相关性。尽管结果比以前BCT凝血酶原时间法与因子II和X的酰胺水解测定法之间不太令人满意的相关性有所改善,但本研究表明,在口服抗凝剂控制中,特异性凝血测定法与广谱外源性凝血试验相比存在局限性。虽然不保证常规使用因子VII发色测定法代替使用BCT的凝血酶原时间,但因子VII酰胺水解测定法为长期患者的剂量提供了有限但可靠的指导。目前形式的技术复杂性不利于其在医院实验室用于常规抗凝控制。